Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.07 USD | -1.83% | -15.08% | -61.37% |
May. 16 | Transcript : Biofrontera Inc., Q1 2024 Earnings Call, May 16, 2024 | |
May. 15 | Earnings Flash (BFRI) BIOFRONTERA Reports Q1 Revenue $7.9M, vs. Street Est of $10.9M | MT |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 128.6 | 24.47 | 4.204 | 5.446 | - | - |
Enterprise Value (EV) 1 | 128.6 | 24.47 | 4.204 | 5.446 | 5.446 | 5.446 |
P/E ratio | -1.76 x | -30.6 x | -0.21 x | -0.25 x | -1.89 x | 2.61 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 5.34 x | 0.85 x | 0.12 x | 0.13 x | 0.11 x | 0.08 x |
EV / Revenue | 5.34 x | 0.85 x | 0.12 x | 0.13 x | 0.11 x | 0.08 x |
EV / EBITDA | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 855 | 1,335 | 1,518 | 5,089 | - | - |
Reference price 2 | 150.4 | 18.33 | 2.770 | 1.070 | 1.070 | 1.070 |
Announcement Date | 4/8/22 | 3/8/23 | 3/15/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | 24.1 | 28.67 | 34.07 | 40.98 | 51.06 | 68.14 |
EBITDA | - | - | - | - | - | - | - |
EBIT 1 | - | -25.2 | -18.58 | -22.68 | -14.14 | -3.221 | 6.053 |
Operating Margin | - | -104.57% | -64.8% | -66.56% | -34.52% | -6.31% | 8.88% |
Earnings before Tax (EBT) 1 | - | -37.66 | -0.608 | -20.12 | -20.41 | -3.171 | 6.153 |
Net income 1 | -10.99 | -37.71 | -0.64 | -20.13 | -20.42 | -3.171 | 6.153 |
Net margin | - | -156.49% | -2.23% | -59.09% | -49.82% | -6.21% | 9.03% |
EPS 2 | -9,590 | -85.60 | -0.6000 | -13.02 | -4.240 | -0.5650 | 0.4100 |
Free Cash Flow | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 5/7/21 | 4/8/22 | 3/8/23 | 3/15/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 9.168 | 9.751 | 4.457 | 4.322 | 10.14 | 8.733 | 5.848 | 8.896 | 10.6 | 7.912 | 9.013 | 7.513 | 16.54 | 12.5 | 9.2 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -1.88 | -3.11 | -6.212 | -3.639 | -5.62 | -5.492 | -8.699 | -4.62 | -3.865 | -5.467 | -4.941 | -6.214 | 2.476 | -1 | -3.2 |
Operating Margin | -20.51% | -31.89% | -139.38% | -84.2% | -55.4% | -62.89% | -148.75% | -51.93% | -36.48% | -69.1% | -54.82% | -82.71% | 14.97% | -8% | -34.78% |
Earnings before Tax (EBT) 1 | -14.5 | 5.591 | -0.85 | -2.565 | -2.784 | -7.473 | -9.823 | -6.341 | 3.52 | -10.44 | -6.141 | -6.264 | 2.426 | -1 | -3.2 |
Net income 1 | -14.5 | 5.561 | -0.85 | -2.566 | -2.785 | -7.478 | -9.837 | -6.342 | 3.526 | -10.44 | -6.141 | -6.264 | 2.426 | -1 | -3.2 |
Net margin | -158.21% | 57.03% | -19.07% | -59.37% | -27.45% | -85.63% | -168.21% | -71.29% | 33.28% | -131.91% | -68.13% | -83.38% | 14.67% | -8% | -34.78% |
EPS 2 | -25.80 | 6.400 | -1.000 | -2.200 | -2.800 | -5.600 | -7.230 | -4.640 | 4.550 | -2.880 | -1.190 | -1.200 | 0.4600 | -0.1900 | -0.5700 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 4/8/22 | 5/13/22 | 8/12/22 | 11/14/22 | 3/8/23 | 5/12/23 | 8/11/23 | 11/9/23 | 3/15/24 | 5/15/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | 0.01 | 0.04 | - | 0.7 | 0.8 | - |
Capex / Sales | - | 0.05% | 0.13% | - | 1.71% | 1.57% | - |
Announcement Date | 5/7/21 | 4/8/22 | 3/8/23 | 3/15/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-61.37% | 5.45M | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- BFRI Stock
- Financials Biofrontera Inc.